Comparative efficacy of intralesional bleomycin sulphate and intra-lesional Immunotherapy with Candida skin testing antigen in the treatment of palmoplantar warts.
- Conditions
- Health Condition 1: null- PALMOPLANTAR WART
- Registration Number
- CTRI/2018/01/011524
- Lead Sponsor
- INDIAN COUNCIL OF MEDICAL RESEARCH
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
1.Age- Adult males and females aged 18-65 years.
2.Multiple plantar warts diagnosed on the basis of history and physical examination by two dermatologists.
Palmoplantar warts will be defined as sharply defined, hyperkeratotic rough lesions with loss of epithelial ridges over the surface of the lesion with a smooth collar of thickened horn present over the palmar or plantar surfaces.
3.Untreated or no treatment in the last four weeks.
1.Known immune-compromised state such as history of HIV infection, on steroids and other immunosuppressive drugs.
2.Past history of immunotherapy or bleomycin sulphate.
3.Warts measuring more than 20cm2 in size.
4.Local site infection.
5.Pregnant and lactating females.
6.Any history of chronic cardiac, renal and pulmonary illness, peripheral vascular disease, Raynaudâ??s disease.
7.Unable to give informed consent.
8.Allergy to components of candida antigen or bleomycin sulphate.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Clearance of wartsTimepoint: Four weeks after the last dose of agent
- Secondary Outcome Measures
Name Time Method CLEARANCE OF DISTANT UNTREATED WARTTimepoint: 4 and 12 weeks after the last dose of agent;Delayed clearance of unresolved wartsTimepoint: 12 weeks after the last dose of agent;Recurrence of completely cleared lesionsTimepoint: 12 weeks after the last dose of agent